Literature DB >> 16040381

IL-15: targeting CD8+ T cells for immunotherapy.

A Diab1, A D Cohen, O Alpdogan, M-A Perales.   

Abstract

IL-15 is a pleiotropic cytokine that plays an important role in both the innate and adaptive immune system. IL-15 promotes the activation of neutrophils and macrophages, and is critical to DC function. In addition, IL-15 is essential to the development, homeostasis, function and survival of natural killer (NK) cells, NK T (NKT) cells and CD8+ T cells. Based on these properties, IL-15 has been proposed as a useful cytokine for immunotherapy. It is currently being investigated in settings of immune deficiency, for the in vitro expansion of T and NK cells, as well as an adjuvant for vaccines. In this paper, we will review the targeting of IL-15 for immunotherapy, with a particular emphasis on its effects on CD8+ T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16040381     DOI: 10.1080/14653240510018037

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  18 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.

Authors:  Yin Guo; Liming Luan; Whitney Rabacal; Julia K Bohannon; Benjamin A Fensterheim; Antonio Hernandez; Edward R Sherwood
Journal:  J Immunol       Date:  2015-07-27       Impact factor: 5.422

3.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

4.  Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Authors:  Mark P Rubinstein; Marek Kovar; Jared F Purton; Jae-Ho Cho; Onur Boyman; Charles D Surh; Jonathan Sprent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

5.  Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen.

Authors:  Wei Zhang; Sheng-Fu Dong; Shu-Hui Sun; Yuan Wang; Guang-Di Li; Di Qu
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

6.  Selective dependence of H2-M3-restricted CD8 responses on IL-15.

Authors:  Jürgen R Müller; Thomas A Waldmann; Sigrid Dubois
Journal:  J Immunol       Date:  2012-02-06       Impact factor: 5.422

7.  CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.

Authors:  Kazue Watanabe; Susumu Suzuki; Michi Kamei; Shingo Toji; Takakazu Kawase; Toshitada Takahashi; Kiyotaka Kuzushima; Yoshiki Akatsuka
Journal:  Int J Hematol       Date:  2008-08-05       Impact factor: 2.490

8.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

Review 9.  Rejuvenation of the aging T cell compartment.

Authors:  Amanda M Holland; Marcel R M van den Brink
Journal:  Curr Opin Immunol       Date:  2009-07-14       Impact factor: 7.486

10.  Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression.

Authors:  Stephanie K Watkins; Bing Li; Katharine S Richardson; Kimberly Head; Nejat K Egilmez; Qun Zeng; Jill Suttles; Robert D Stout
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.